PTC Therapeutics, Inc. (PTCT)
NasdaqGS
Price as at 1 Oct 2026, 04:00 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
PTC Therapeutics, Inc. trades at $64.78. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
11 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- D. E. Shaw, D. E. Shaw & Co., Inc.$126.35M · 0.1% of book
- Ken Griffin, CITADEL ADVISORS LLC$61.00M · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$59.02M · 0.1% of book
- Marshall Wace, MARSHALL WACE, LLP$57.49M · 0.1% of book
- Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$53.38M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in PTCT
Trades in PTCT disclosed by members of Congress and executive-branch officials, latest first:
- Donald J Trump · Executive branchSell · $50,001 - $100,000 · traded 30 Apr 2026 · disclosed 1 Jul 2026
- Donald J Trump · Executive branchSell · $15,001 - $50,000 · traded 29 Jul 2024 · disclosed 22 Sept 2026
- Donald J Trump · Executive branchBuy · $15,001 - $50,000 · traded 22 Jun 2024 · disclosed 22 Aug 2026
- Donald J Trump · Executive branchBuy · $15,001 - $50,000 · traded 4 Jun 2024 · disclosed 22 Aug 2026
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
Common questions
Which funds own PTCT?
11 of the institutions we track reported a position in PTCT in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its PTCT data?
Fundamentals for PTCT come from company filings and exchange data, as listed on NasdaqGS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 04:00 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for PTCT, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.